Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) Shares Outstanding (Diluted Average) (2021 - 2025)

Journey Medical's Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $24.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 19.9% year-over-year to $24.5 million, compared with a TTM value of $24.5 million through Dec 2025, up 19.9%, and an annual FY2025 reading of $24.5 million, up 19.9% over the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $24.5 million at Journey Medical, up from $23.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $24.5 million in Q4 2025, with the low at $9.2 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $18.3 million, with a median of $18.2 million recorded in 2023.
  • Year-over-year, Shares Outstanding (Diluted Average) skyrocketed 92.33% in 2022 and then fell 4.26% in 2024.
  • Tracing DERM's Shares Outstanding (Diluted Average) over 5 years: stood at $10.2 million in 2021, then surged by 72.05% to $17.5 million in 2022, then grew by 4.0% to $18.2 million in 2023, then rose by 12.06% to $20.4 million in 2024, then rose by 19.9% to $24.5 million in 2025.
  • Per Business Quant, the three most recent readings for DERM's Shares Outstanding (Diluted Average) are $24.5 million (Q4 2025), $23.6 million (Q3 2025), and $23.0 million (Q2 2025).